# Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

> **NCT02980874** · PHASE3 · TERMINATED · sponsor: **Clearside Biomedical, Inc.** · enrollment: 460 (actual)

## Conditions studied

- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** suprachoroidal CLS-TA
- **DRUG:** suprachoroidal sham
- **DRUG:** IVT aflibercept

## Key facts

- **NCT ID:** NCT02980874
- **Lead sponsor:** Clearside Biomedical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-31
- **Primary completion:** 2018-12-10
- **Final completion:** 2018-12-10
- **Target enrollment:** 460 (ACTUAL)
- **Why stopped:** Primary, 8-week efficacy endpoint not achieved. No additional benefit for subjects receiving a corticosteroid together with an intravitreal anti-VEGF agent.
- **Last updated:** 2021-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980874, "Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02980874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*